FX.co ★ Nuvalent Announces Public Offering Of $350 Mln Of Shares

Nuvalent, Inc. (NUVL), a biotechnology company specializing in cancer therapies, announced on Monday the launch of a $350 million underwritten public offering of its Class A shares. All shares in this offering are being issued by Nuvalent.

The company anticipates providing the underwriters with a 30-day option to acquire up to an additional 15% of the Class A shares initially offered.

J.P. Morgan, TD Cowen, Jefferies, and Stifel are serving as joint book-running managers for this offering.